Drugs / TBX-2400
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04709458 | Sep 2022 → Aug 2024 | acute myeloid leukemia, myelofibrosis | Taiga Biotechnologies, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBX-2400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04709458 ↗ |
| Modality | Cell therapy | “allogeneic stem cell transplantation with TBX-2400” NCT04709458 ↗ |
| Route | Intravenous | “Single intravenous infusion of TBX-2400” NCT04709458 ↗ |